NasdaqGM:CRMDPharmaceuticals
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results
In May 2026, CorMedix Inc. reported first-quarter 2026 revenue of US$127.43 million and net income of US$38.6 million, and raised its full-year 2026 net revenue guidance to a range of US$325 million to US$345 million.
The quarter also featured positive Phase III topline results for REZZAYO in prophylaxis and continued advancement of DefenCath and taurolidine/heparin programs, underscoring how CorMedix is tying commercial growth to late-stage pipeline progress.
Next, we’ll explore how...